BRCA1 Antibodies

Breast cancer type 1 susceptibility protein (BRCA1)

It is unclear whether it also mediates the formation of different kinds of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function.

The BRCA1-BARD1 heterodimer coordinates a wide range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Required for normal cell cycle progression from G2 into mitosis.

Gene Information

Human
Gene Name:	BRCA1
Uniprot:	P38398
Entrez:	672

Family

Belongs to:
No superfamily

Alternative Names

BRCA1; BRCAI; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein; breast cancer 1, early onset; breast cancer type 1 susceptibility protein; EC 6.3.2; EC 6.3.2.-; IRIS; PNCA4; PSCP; subunit 1

Molecular Weight

Mass (kDA):
207.721 kDA

Genomic Context

Human
Location:	17q21.31
Sequence:	17; NC_000017.11 (43044295..43125364, complement)

Tissue Specificity

Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.

Subcellular Localizations

Nucleus. Chromosome. Cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by ABRAXAS1 and the BRCA1-A complex (PubMed:26778126). Translocated to the cytoplasm during UV-induced apoptosis (PubMed:20160719).; [Isoform 3]: Cytoplasm.; [Isoform 5]: Cytoplasm.

Diseases

• Malignant Neoplasms
• Mammary Neoplasms
• Malignant Neoplasm Of Breast
• Neoplasms
• Malignant Neoplasm Of Ovary
• Ovarian Neoplasm
• Carcinoma
• Brca1 Gene Mutation
• Brca2 Gene Mutation
• Cell Transformation, Neoplastic
• Hereditary Breast Carcinoma
• Carcinogenesis
• Epithelial Ovarian Cancer

• Malignant Paraganglionic Neoplasm
• Sporadic Breast Carcinoma
• Neoplasm Metastasis
• Ductal Breast Carcinoma
• Malignant Neoplasm Of Prostate
• Hereditary Breast And Ovarian Cancer Syndrome
• Adenocarcinoma

Interacting Proteins

• ABRAXAS1
• ACACA
• BAP1
• BARD1
• BCL2

• BRAP
• BRAT1
• BRIP1
• CCND1
• CCNE1

• CHEK1
• ESR1
• ESR2
• Ezh2
• FHL2

• GTF2I
• H2AFX
• HMMR
• HSPD1
• IFI16

• KPNA2
• MDC1
• NELFB
• PALB2
• PIN1

• PPP1CA
• PPP1CB
• PPP1CC
• RBBP8
• SUMO1

• SUMO2
• TOP2A
• TP53BP1
• UIMC1
• ZCCHC8

• ZNF350

Pathways

• Dna Repair
• Cell Cycle
• Localization
• Methylation
• Pathogenesis
• Cell Proliferation
• Cell Death
• Dna Replication
• Cell Growth
• Hypersensitivity
• Cell Cycle Arrest
• Dna Methylation
• S Phase

• Mitosis
• Double-strand Break Repair
• Cell Cycle Checkpoint
• Translation
• Mismatch Repair
• Menopause
• Dna Damage Checkpoint

PTMs

• Phosphorylation
• Methylation
• Ubiquitination
• Cleavage
• Acetylation
• Dephosphorylation
• Demethylation
• Sumoylation
• Deacetylation

• Reduction
• Nitration
• Glycosylation
• Carboxylation
• Oxidation
• Deamination
• Hydroxylation
• Ribosylation
• Biotinylation

Research Areas

• Apoptosis
• Breast Cancer
• Cancer
• Cell Biology
• Chromatin Research

• DNA Double Strand Break Repair
• DNA Repair
• Homologous Recombination
• Tumor Suppressors
• Ubiquitin Proteasome Pathway

• Zinc Finger

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/BRCA1

Best Uses Of The BRCA1 Marker

Biological assays employ antibodies to detect BRCA1. These antibodies can be polyclonal or monoclonal, and are able to bind to BRCA1 in variety of animal samples. Boster Bio uses rabbit and mouse as models for its antibodies against BRCA1. The BRCA1-BARD1 heterodimer coordinates a variety of cellular pathways including DNA damage repair, transcriptional regulation, genomic stability, and cell cycle progression into mitosis.

PIM1

The BRCA1 gene is expressed in all breast cancers. However, the expression of the gene differs greatly between patients. This could be due to a variety of reasons but is usually related to inherited cancer. The BRCA1 gene can be highly expressed in a few people which causes it to be associated with more breast cancers than others. It could also be present in individuals without a genetic mutation.

Researchers have discovered an unquestionably strong link between tumor markers in serum and BRCA1/2 mutation status. These findings were used to construct differentiative models for ovarian cancer diagnosis and stratification. They have also been proven to be effective in predicting the risk of metastasis. These markers can be used to identify Ovarian cancer, however more research is needed. These markers could soon be standard in the clinical setting. This opens the possibility of personalized medical treatment.

A new study of research has identified the mutation in the BRCA1 gene by analysing DNA from blood samples. The human BRCA1/2 Sequencing Panel Kit from Sansure Biotech was used by the researchers. This kit is beneficial for enrichment and sequencing and amplifies entire exons that code and boundaries between exons. These studies were published in peer-reviewed journals.

Mammaglobin A

MammaglobinA is one of the proteins found in breast cancer. It has been suggested to be a indicator of micrometastasis. Although routine histology tests can detect it, the exact role of mammaglobin is not known. The literature on the subject is highly contradictory. While mammaglobin has been linked to a higher risk of breast cancer, it isn't a reliable marker for aggressive or low-grade tumors.

Consult your physician If you think you be suffering from BRCA1 or BRCA2. The BRCA1 gene variant raises the risk of developing ovarian and breast cancer, but it's not the sole cause. There are two types of mammaglobin A: Fanconi anemia and atypical anemia. Both subtypes have similar symptoms, however they are treated differently.

SCGB2A2

The BRCA1 antibodies and antisera are among the most potent BRCA1 markers. Boster provides high-affinity primary antibodies that are referenced in a range of research papers. The antibodies have been validated for high specificity and affinity and Boster provides product credits to the first reviewer. Boster is the industry leader in this field and offers antibodies for all genes from human to mouse.

There are a myriad of biological assays which make use of antibodies to identify BRCA1 in various animal samples. Boster Bio's BRCA1 antisera are created using rabbit and mouse tissues. The BRCA1/BARD1 heterodimer coordinates a variety of cell-based pathways, including transcriptional regulation and genomic stability. Furthermore, it is essential for the progression of the cell cycle to mitosis.

FOXA1

While its clinical significance is not yet known, the presence of FoxA1 in breast cancer is linked with an improved prognosis. Numerous studies have proven that the expression of the gene is linked to the likelihood of recurrence as well as overall survival. The marker is associated with a better prognosis that several other well-known indicators such as the progesterone receptacle Ki67 or ER status. Further research is required to determine the best way to use the FOXA1 marker.

The connection of the FOXA1 gene with ER was first identified in the promoter region of the estrogen-regulated Vitellogenin B1 gene. This was possible because of high-throughput technology. It also allowed for the later discovery of the extensive connection between FOXA1 and the hormone nuclear receptors. To study the ER/FoxA1 interactions on the 21st chromosome, immunoprecipitation of chromatin is used.

Profiles of Methylation

The Methylation profiles of the BRCA1, BRCA2 and RASSF1A markers were utilized in this meta-analysis. This meta-analysis provides new theoretical information about BRCA1 methylation, breast cancer, and RASSF1A markers. Particularly, the methylation profiles of these genes could be used in future research to identify new biomarkers to aid in the diagnosis and treatment of breast cancer. However, there are limitations associated with this type of meta-analysis.

The profiles of methylation of the BRCA1 promoter were examined in sporadic and hereditary breast cancer. This methylation was particularly prominent in sporadic ovarian cancer however, it was not present in germ-line BRCA1 mutations. It is also worth noting that BRCA2 is not associated with the same methylation pattern in cancer of the ovary. While previous studies suggested that BRCA2 levels of methylation could be low in ovarian cancer There aren't any studies to support this assertion.

The current study showed that BRCA1 hypermethylation was linked with basal-like characteristics and PD -L1 transcription. In patients suffering from TNBC, BRCA1 promoter hypermethylation was associated with a better prognosis. It was challenging to standardize and implement the IHC assay. Additionally there are numerous variables that can affect the IHC results. It is important to remember, however, that BRCA1 promoter hypermethylation status in tumor samples is strongly linked to BRCA1 marker expression.

ROC analysis

ROC analysis was employed to evaluate the accuracy of BRCA1 markers. The BRCA1 marker's sensitivity as well as specificity were determined for wildtype and BRCA mutation carrier subgroups respectively. The AUC was 0.931, 0.942, and 0.946, respectively. The results of this analysis were comparable among these subgroups. In addition the marker was able to discern healthy BRCA1 mutation carriers and wildtype women.

This study investigated the diagnostic power of various methods of detection. It combined detection of serum proteins and gene markers. It detected Myc, BRCA-1, and C-erbB2. ELISA was used to detect levels of these proteins as well as gene markers. By using a t-test, ROC curves were also calculated. The results suggested that the detection of all three markers was superior than the separate detection of any one of them.

The results of this study were based on an examination of 232 women suffering from cancer of the ovary, and 219 women who had a family history of ovarian cancer. The markers were tested to determine the boundaries of BRCA1/2 exons introns. A discriminative model was created using the markers for tumors in serum as well as BRCA1/2 mutation status. It was able to detect an ovarian cancer with a high degree of accuracy and the sensitivity. The results suggest that blood tests can detect the presence of ovarian cancer in patients with an BRCA mutation.

Clinical significance

Some types of cancer are rooted in the BRCA1 gene. In other cancers it is the BRCA gene is non-specific. The BRCA1 gene is thought to be involved in cancer pathogenesis and treatment decision-making screening, screening, or screening. About 20% of all human cancers are caused by the BRCA1 gene. This is an important change compared to previous studies. BRCA1 is an indicator of an inherited gene mutation that is linked to tumorigenesis.

Researchers discovered that breast and ovarian cancers are more prevalent in women who have a mutation in BRCA1. The BRCA1 gene plays a function in cell responses to DNA damage. The central region of BRCA1 are also associated with a higher risk of ovarian and breast cancer. However, there are still many limitations in identifying individuals with BRCA1 gene mutations.

IHC workflow

For IHC tissues, samples are obtained from different sources which include animal models, biopsy, and surgical procedures. The latter method gives fresh tissue samples, whereas autopsy is the process of killing an animal. However, the tissue sample obtained from the latter process should be fixed as soon as the animal has passed away, because antigens could degrade over time. These are some tips. Learn more about how to use IHC to detect BRCA1 markers.

The first step is to dip fresh slides in cleaning solution for 12 to 24 hours. The slides must then be rinsed at least five times in 95% ethanol and distilled water. Then, they should be completely dried using simple wiping or using an infrared oven to prevent scratches. Microscopic slides must be between five and seven micrometers thick. Nervous tissue slides are between 20 and 100 millimeters thick. This permits better tracking of the never fiber direction. The process for treating a coverslip is the same as that for microscopic slides, however, it is using an elongated coverslip.